---
schema_version: "secwatch.filing_event.v1"
accession: "0001370053-25-000002"
form_type: "8-K"
ticker: "ANAB"
cik: "0001370053"
company_name: "ANAPTYSBIO, INC"
filed_at: "2025-02-03T23:59:59+00:00"
generated_at: "2026-05-27T03:56:11.831870+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AnaptysBio licenses imsidolimab to Vanda for $15M upfront; BLA/MAA prep underway

## Summary
- Anaptys receives $10M upfront and $5M for drug supply; eligible for up to $35M in milestones and 10% royalty on net sales.
- Imsidolimab, an IL-36R antagonist, completed two global Phase 3 trials (GEMINI-1 and GEMINI-2) in Generalized Pustular Psoriasis.
- Vanda plans to begin BLA and MAA submissions in the US and EU in 2025, leveraging its rare disease and anti-inflammatory expertise.
- Positive Phase 3 data showed rapid disease clearance after single dose, maintained clear skin for at least 24 weeks with no safety signals.

## SEC filing metadata
- accession: 0001370053-25-000002
- form_type: 8-K
- ticker: ANAB
- cik: 0001370053
- company_name: ANAPTYSBIO, INC
- filed_at: 2025-02-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000002/0001370053-25-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1370053/000137005325000002/anab-20250131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001370053-25-000002
- JSON: https://secwatch.observer/filing/0001370053-25-000002.json
- Plain text: https://secwatch.observer/filing/0001370053-25-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.